CARM (CARISMA Therapeutics) Common Stock: $0.04 Mil (As of Sep. 2025)


What is CARISMA Therapeutics Common Stock?

CARISMA Therapeutics CARM Common Stock is $0.04 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

CARISMA Therapeutics's quarterly common stock stayed the same from Mar. 2025 ($0.04 Mil) to Jun. 2025 ($0.04 Mil) and stayed the same from Jun. 2025 ($0.04 Mil) to Sep. 2025 ($0.04 Mil).

CARISMA Therapeutics's annual common stock increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.04 Mil) and increased from Dec. 2023 ($0.04 Mil) to Dec. 2024 ($0.04 Mil).

CARISMA Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Common Stock Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
0.00 0.00 0.00 0.04 0.04

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.04 0.04 0.04

CARISMA Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.04 Mil mean?
CARISMA Therapeutics (CARM) has a Common Stock of $0.04 Mil as of Sep. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on CARISMA Therapeutics and its competitors.
Is CARISMA Therapeutics' Common Stock too high?
CARISMA Therapeutics' current Common Stock is $0.04 Mil.
How does CARISMA Therapeutics' Common Stock compare to SCPX and CYTOF?
CARISMA Therapeutics' Common Stock of $0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current Common Stock is $0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current Common Stock is $0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current Common Stock is $0.04 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.